Ozempic (semaglutide) has been the talk of the nation, more so for its use for weight loss rather than its actual Food and Drug Administration (FDA) indication, type 2 diabetes mellitus
In December 2017, the injectable formulation of semaglutide received approval from the U.S
Over the past decades, several randomized clinical trials (RCTs) have shown that GLP-1 RAs improve cardiovascular outcomes in patients with type 2 DM (T2DM) who have established CVDs or are at risk, as well as in individuals with CKD [16,17,18,19]
Summative interaction between astaxanthin, Ginkgo biloba extract (EGb761) and vitamin C in Suppression of respiratory inflammation: a comparison with ibuprofen
I think there's a lot of interest both from patients as well as from the pharmaceutical industry to try and find ways where you can actually both get a better treatment, you can also get a better adherence, and less impact on people's lives that they have to remember
These medications help: Slow stomach emptying, leading to increased feelings of fullness Reduce appetite and food intake by acting on brain centers that control hunger Improve insulin secretion and sensitivity Lower blood sugar levels, especially after meals Promote weight loss through multiple mechanisms Mounjaro (tirzepatide) is actually a dual GIP/GLP-1 receptor agonist, meaning it acts on two hormonal pathways related to blood sugar control and appetite regulation, which may explain its particularly strong effects on weight loss